Prestige Biologics (KOSDAQ:334970) secured a contract to manufacture active pharmaceutical ingredients from an undisclosed client, according to a Wednesday filing with the Korea Exchange.
The contract, valued at 2.67 billion won, is valid till March 31, 2027.
Shares of Prestige Biologics added nearly 2% at market close.